

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

CELGENE CORPORATION,	:	
	:	
Plaintiff,	:	Civ. Action No. 17-3387 (ES)(MAH)
	:	(Consolidated)
-v-	:	
	:	
HETERO LABS LIMITED; HETERO	:	
LABS LIMITED UNIT-V; HETERO	:	
DRUGS LIMITED; HETERO USA, INC.;	:	
AUROBINDO PHARMA LIMITED;	:	
AUROBINDO PHARMA USA, INC.;	:	
AUROLIFE PHARMA LLC; EUGIA	:	
PHARMA SPECIALTIES LIMITED;	:	
APOTEX INC.; APOTEX CORP.;	:	
MYLAN PHARMACEUTICALS, INC.;	:	
MYLAN INC.; MYLAN, N.V.;	:	
BRECKENRIDGE PHARMACEUTICAL,	:	
INC.; and TEVA PHARMACEUTICALS	:	
USA, INC.,	:	AMENDED SCHEDULING ORDER:
	:	
Defendants.	:	
	:	

This matter having come before the Court for a telephone conference held on the record on June 18, 2020;

and for the reasons set forth on the record on June 18, 2020;

and for good cause shown;

IT IS on this 18th day of June 2020,

ORDERED that the April 3, 2020 Amended Scheduling Order [D.E. 684] is amended as follows, and that the below dates shall govern the trial, pre-trial, and post-trial proceedings:

Rebuttal Expert Reports: September 4, 2020

Reply Expert Reports: October 2, 2020

Close of Expert Discovery: November 13, 2020

Pretrial Order with Executive Summary:	December 18, 2020
Trial Briefs:	December 18, 2020
Pretrial Conference:	January 4, 2021 at 12:00 p.m.
Trial:	January 11, 2021
Exchange Initial Findings of Fact:	One week after conclusion of trial
Exchange Responsive Findings of Fact:	Two weeks after conclusion of trial
Joint Proposed Findings of Fact:	Three weeks after conclusion of trial
Proposed Conclusions of Law:	Three weeks after conclusion of trial

and it is further

ORDERED that these deadlines shall not be extended absent significant, further exigent circumstances; and it is further

ORDERED that the parties shall provide the Court with proposed dates for the next telephone conference, as needed.

s/Michael A. Hammer

UNITED STATES MAGISTRATE JUDGE